Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2019-05-21 Board/Management Inform…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION
Board/Management Information Classification · 95% confidence The document lists the members of the board of directors, their roles, and committee memberships. It focuses on governance structure and board composition without financial data or report content. This matches the description of Board/Management Information (MANG), which covers announcements of changes or details about the company's board or senior management. The document is short and does not present financial results or other report types.
2019-05-21 English
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2019
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Results For the three months ended 31 March 2019' and contains detailed unaudited consolidated financial statements, including profit or loss, comprehensive income, segment information, and earnings per share for the quarter ended March 31, 2019. It explicitly states that the financial data is for the three months ended 31 March 2019 and is unaudited, which aligns with an Interim / Quarterly Report. The document is lengthy (over 12,000 characters) and contains substantive financial data and analysis, not just an announcement or summary. There is no indication that this is a full Annual Report (10-K) or just an earnings release (ER) which typically contains only key highlights. The presence of detailed segment data, notes on accounting policies, and comprehensive income statements confirms it is a quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2019
2019-05-21 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2019
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, including share options, warrants, convertibles, and other share-related transactions for the month ended 30/4/2019. The document includes confirmations by a director regarding compliance with listing rules and legal requirements related to securities issued during the month. There are no financial statements or financial performance data presented, nor is this a report of earnings or management discussion. The content focuses on share capital changes and confirmations related to securities issuance, which aligns with announcements regarding share capital changes rather than a full financial report or earnings release. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length and detail confirm it is not a brief announcement but a substantive monthly return on share capital movements.
2019-05-20 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the unaudited first quarterly results for the three months ended 31 March 2019. It does not contain the actual financial results or detailed financial data, but merely announces the upcoming board meeting where such results will be approved. The document length is only 1456 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, announcements about report approvals or meetings without substantive financial data should be classified as Regulatory Filings (RNS).
2019-05-08 English
VOLUNTARY ANNOUNCEMENT - FORMATION OF JOINT VENTURE
Capital/Financing Update Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the formation of a joint venture with Shanghai Haihe Pharmaceutical Co., Ltd. It details the establishment of Shanghai Haishi Biopharmaceutical Co., Ltd., the equity interests, and the transfer of rights and obligations related to five new drug projects. The content focuses on a corporate transaction (joint venture formation) and does not contain financial statements, audit information, or regulatory certifications. It is not an annual report, earnings release, or any form of financial report. The announcement is about a corporate development related to business operations and partnerships, which fits best under Capital/Financing Update (CAP) as it involves a significant corporate financing and structural change (joint venture formation). The document length is about 4988 characters, which is sufficient for a detailed announcement rather than a brief notice. Therefore, the appropriate classification is CAP with high confidence.
2019-05-07 English
INSIDE INFORMATION - PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF CSPC INNOVATION PHARMACEUTICAL CO., LTD .* FOR THE THREE MONTHS ENDED 31 MARCH 2019
Interim / Quarterly Report Classification · 95% confidence The document is an announcement by CSPC Pharmaceutical Group Limited regarding the principal accounting data and financial indicators of its subsidiary CSPC Innovation Pharmaceutical Co., Ltd. for the three months ended 31 March 2019. It references the quarterly report published by the subsidiary on the Shenzhen Stock Exchange and provides detailed financial data including balance sheet, income statement, and cash flow statement items with comparative figures and explanations for changes. The document is over 10,000 characters and contains substantive financial data and analysis for a period shorter than a full fiscal year (quarterly). It is not merely an announcement of a report publication but includes detailed financial information. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2019-04-28 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.